J9999 HCPCS Level II code: Not otherwise classified, antineoplastic drugs
J9999 is the HCPCS code for “Not otherwise classified, antineoplastic drugs” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J9999Not otherwise classified, antineoplastic drugs
Short description: Chemotherapy drug
HCPCS · United States
Medicare details
The indicators CMS publishes with J9999 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Chemotherapy
- Added
- Jan 1, 1986
Where J9999 sits
- 1J codesDrugs administered other than orally
- 2Active code J9999Not otherwise classified, antineoplastic drugs
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J9999 mean?
J9999 is the HCPCS code for “Not otherwise classified, antineoplastic drugs” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J9999?
CMS lists J9999’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J9999
All J codesJ9393Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mgJ9394Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mgJ9395Injection, fulvestrant, 25 mgJ9400Injection, ziv-aflibercept, 1 mgJ9600Injection, porfimer sodium, 75 mgJ9601Injection, linvoseltamab-gcpt, 1 mg